Please assess the completion status of the following clinical trial:

Trial Title: Modulation of Cerebral Blood Flow Using Iron Chelators

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adults between the ages of 18-80 years.~Exclusion Criteria:~* subjects taking vasoactive medications,~* hypertension,~* pregnant women, smokers,~* COPD,~* asthma,~* diabetes mellitus,~* intracranial or carotid stenosis,~* hepatic disease,~* renal disease,~* bone marrow suppression,~* cardiac disease,~* heart failure,~* iron deficiency,~* history of cancer,~* history of head trauma,~* subarachnoid hemorrhage,~* central nervous system vasculitis,~* multiple sclerosis,~* migraines,~* seizures,~* sickle cell disease or trait,~* cardiac arrhythmia,~* unable to give informed consent, or~* poor transcranial Doppler insonation windows.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Healthy young (Type: EXPERIMENTAL): Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
- healthy old (Type: EXPERIMENTAL): Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.

Based on this trial design, predict the completion outcome and termination type (if applicable).